Macrolide use in the previous years is associated with failure to eradicate Helicobacter pylori with clarithromycin‐containing regimens
Impacto
Scholar |
Otros documentos de la autoría: Muñoz Gómez, Pablo; Jordán Castro, Junior Alexander; Abanades Tercero, María; Blanco González, José Javier; Andrés Esteban, Eva María; Valle-Muñoz, Julio
Metadatos
Mostrar el registro completo del ítemcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/36080
comunitat-uji-handle3:10234/36082
comunitat-uji-handle4:
INVESTIGACIONEste recurso está restringido
https://doi.org/10.1111/hel.12452 |
Metadatos
Título
Macrolide use in the previous years is associated with failure to eradicate Helicobacter pylori with clarithromycin‐containing regimensAutoría
Fecha de publicación
2018-02Editor
WileyCita bibliográfica
MUÑOZ GÓMEZ, Pablo; JORDÁN CASTRO, Junior Alexander; ABANADES TERCERO, María; BLANCO GONZÁLEZ, José Javier; ANDRÉS ESTEBAN, Eva María; VALLE MUÑOZ, Julio. (2018). Macrolide use in the previous years is associated with failure to eradicate Helicobacter pylori with clarithromycin‐containing regimens. Helicobacter, v. 23, n. 1Tipo de documento
info:eu-repo/semantics/articleVersión de la editorial
https://onlinelibrary.wiley.com/doi/abs/10.1111/hel.12452Versión
info:eu-repo/semantics/publishedVersionPalabras clave / Materias
Resumen
Abstract
Background: There is some evidence that prior use of macrolide antibiotics is a useful
predictor of the likelihood of standard triple therapy failure in Helicobacter pylori eradi-
cation. In this study, ... [+]
Abstract
Background: There is some evidence that prior use of macrolide antibiotics is a useful
predictor of the likelihood of standard triple therapy failure in Helicobacter pylori eradi-
cation. In this study, we have evaluated whether previous intake of macrolides corre-
lates with failure to eradicate H. pylori using two different first- line
clarithromycin- containing regimens.
Materials and Methods: Retrospective study of 212 patients with H. pylori infection
treated with one of two first- line clarithromycin- containing regimens: 108 patients
treated with triple therapy for 10 days and 104 patients treated with concomitant
therapy for 10 days. The intake of macrolides (clarithromycin, azithromycin, and other
macrolides) prior to the eradication therapy was obtained from the electronic medical
record, which contains information regarding all the medication prescribed to the pa-
tients since the year 2004.
Results: One hundred of 212 patients (47.2%) had received at least one treatment
with macrolides during the years prior to the eradication therapy. H. pylori eradication
rates were significantly lower in patients with previous use compared to patients with-
out previous use of macrolides, both with triple therapy (60.8% vs 92.9%; P < .0001)
and with concomitant therapy (85.7% vs 98.2%; P = .024).
Conclusions: Previous use of macrolides correlates with a low H. pylori eradication rate
with triple and concomitant clarithromycin- containing regimens. In addition, our study
shows that in patients without previous use of macrolides, triple therapy achieves per-
protocol eradication rates over 90%. [-]
Publicado en
Helicobacter (2018), v. 23, n. 1Derechos de acceso
http://rightsstatements.org/vocab/CNE/1.0/
info:eu-repo/semantics/restrictedAccess
info:eu-repo/semantics/restrictedAccess
Aparece en las colecciones
- MED_Articles [671]